This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2023 Apr 1;41(10):1951-1952.

doi: 10.1200/JCO.22.02691. Epub 2023 Jan 30.

Reply to E.R.S. Cliff et al

Anita D'Souza¹, Shaji Kumar¹

Affiliations

Affiliation

¹ Anita D'Souza, MD, Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; and Shaji Kumar, MD, Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.

PMID: 36716406
DOI: 10.1200/JCO.22.02691

Comment

Reply to E.R.S. Cliff et al

Anita D'Souza et al. J Clin Oncol. 2023.

. 2023 Apr 1;41(10):1951-1952.

doi: 10.1200/JCO.22.02691. Epub 2023 Jan 30.

Authors

Anita D'Souza¹, Shaji Kumar¹

Affiliation

¹ Anita D'Souza, MD, Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; and Shaji Kumar, MD, Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.

PMID: 36716406
DOI: 10.1200/JCO.22.02691

No abstract available

PubMed Disclaimer

Comment on

Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma.
Cliff ERS, Reynolds G, Popat R, Teh BW, Kesselheim AS, Mohyuddin GR. Cliff ERS, et al. J Clin Oncol. 2023 Apr 1;41(10):1949-1951. doi: 10.1200/JCO.22.02197. Epub 2023 Jan 30. J Clin Oncol. 2023. PMID: 36716411 No abstract available.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.